Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis
NCT03829917Phase 3Completed
- Sponsor
- Fundación Nacional de Dermatología
- Start
- Feb 2019
- Primary completion
- Dec 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cutaneous leishmaniasis (CL) comparing Paromomycin and Miltefosine, Miltefosine and Paromomycin (3 arms). Primary endpoint: Change in Size of cutaneous ulcers at 6 months. Started Feb 2019; status: completed.
02
Drugs
miltefosineparomomycin
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT03829917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03829917.